Author: [AUTHOR] Published on 12/1/2019 12:00:00 AM
Hechuan Wang, MS, University of Maryland, Baltimore, MD
Hechuan joined ASCPT because she views it as a large and influential community for people who work in the areas of clinical pharmacology and translational science. She believes that being a member of ASCPT provides her with rich resources for learning more about these important fields. She specifically points to the webinar program that presents information on many relevant topics. She goes on to point out that ASCPT provides opportunities to network with colleagues in academia, regulatory agencies, and industry.
Clinical pharmacology and translational science can induce active collaboration between basic and clinical research. Hechuan is drawn to the field for this reason. She is interested in helping create better treatments for patients. She believes that the principles extracted from basic research can provide guidance to clinical trial design and personalized medicine, which in turn can help accelerate drug development and make them more economical.
In 2015, Hechuan joined the Center for Translational Medicine at the University of Maryland School of Pharmacy. Her research interests focus on utilizing quantitative methods to promote drug development and optimize clinical therapeutics in the areas of oncology and antimicrobials. Hechuan is working on optimizing clinical therapeutics in antimicrobials via a Bayesian approach to adaptive individualized therapeutic management. Adaptive individualized therapeutic management allows for more effective patient care.
Hechuan works on a few other projects, including model‐based dose recommendations for clofarabine as part of pretransplantation conditioning in pediatric subjects before hematopoietic cell transplantation. She is also working on US Food and Drug Administration animal rule‐based drug development of a lead compound for the treatment of sub‐lung syndrome of acute radiation syndrome.